Patient 4 and Patient 11 had no response to the CD19 CAR-T cell infusion and anti-PD-1 antibody therapy and had a poor prognosis (indicated by BCL-2/C-myc double-positive expression, P53 deficiency and a large tumor bulk). Here, CD19 is linked to neoplasm.